Thyrocare Technologies Ltd
NSE:THYROCARE

Watchlist Manager
Thyrocare Technologies Ltd Logo
Thyrocare Technologies Ltd
NSE:THYROCARE
Watchlist
Price: 970 INR -2.98%
Market Cap: 51.4B INR
Have any thoughts about
Thyrocare Technologies Ltd?
Write Note

Thyrocare Technologies Ltd
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Thyrocare Technologies Ltd
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Thyrocare Technologies Ltd
NSE:THYROCARE
Income from Continuing Operations
â‚ą761.9m
CAGR 3-Years
-23%
CAGR 5-Years
-3%
CAGR 10-Years
N/A
Dr Agarwal's Eye Hospital Ltd
BSE:526783
Income from Continuing Operations
â‚ą489.3m
CAGR 3-Years
108%
CAGR 5-Years
34%
CAGR 10-Years
32%
Dr. Lal PathLabs Ltd
NSE:LALPATHLAB
Income from Continuing Operations
â‚ą4.1B
CAGR 3-Years
0%
CAGR 5-Years
12%
CAGR 10-Years
N/A
Vijaya Diagnostic Centre Ltd
NSE:VIJAYA
Income from Continuing Operations
â‚ą1.2B
CAGR 3-Years
12%
CAGR 5-Years
21%
CAGR 10-Years
N/A
Krsnaa Diagnostics Ltd
NSE:KRSNAA
Income from Continuing Operations
â‚ą568.4m
CAGR 3-Years
-33%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Metropolis Healthcare Ltd
NSE:METROPOLIS
Income from Continuing Operations
â‚ą1.4B
CAGR 3-Years
-19%
CAGR 5-Years
2%
CAGR 10-Years
N/A
No Stocks Found

Thyrocare Technologies Ltd
Glance View

Market Cap
51.4B INR
Industry
Health Care

Thyrocare Technologies Ltd. engages in provison of indepedent diagnostic and pathological laboratory services. The company is headquartered in Navi Mumbai, Maharashtra and currently employs 2,115 full-time employees. The company went IPO on 2016-05-09. The firm operates with a centralized processing laboratory (CPL) in Mumbai, India for esoteric tests, and regional processing laboratory in metro cities of India and other parts of Asia. The firm offers technologies, including Chemiluminescence Immunoassay (CLIA), Enzyme Linked Immunosorbent Assay (ELISA), High Performance Liquid Chromatography (HPLC), Capillary Electrophoresis (CE), Ion Selective Electrode (ISE), Fluorescence Flow Cytometry, Nephelometry, Photometry, Liquid Chromatography Mass Spectrometry (LC-MS), Inductively Coupled Plasma-Mass Spectrometry (ICP-MS) and Cytogenetics. The firm offers various kinds of tests, such as Aarogyam X, Aarogyam XL, Aarogyam 1.1, Aarogyam 1.2 and Covid Antibody GT. The company also offers Thyroxine (T4), Triiodothyronine (T3), Thyroid-stimulating hormone and Complete Vitamin Profile tests.

THYROCARE Intrinsic Value
586.07 INR
Overvaluation 40%
Intrinsic Value
Price

See Also

What is Thyrocare Technologies Ltd's Income from Continuing Operations?
Income from Continuing Operations
761.9m INR

Based on the financial report for Jun 30, 2024, Thyrocare Technologies Ltd's Income from Continuing Operations amounts to 761.9m INR.

What is Thyrocare Technologies Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-3%

Over the last year, the Income from Continuing Operations growth was 27%. The average annual Income from Continuing Operations growth rates for Thyrocare Technologies Ltd have been -23% over the past three years , -3% over the past five years .

Back to Top